Quick Answer
MoonLake Immunotherapeutics reported Total Assets of $424.43 million for the year ending 2025.
- MoonLake Immunotherapeutics showed a decrease of -11.2% in Total Assets from 2024 to 2025.
- This data is from MoonLake Immunotherapeutics's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $163.5 thousand | Q1 2021: $116.49 million | Q2 2021: $116.37 million | Q3 2021: $116.25 million | Q1 2022: $231.21 million | Q2 2022: $98.43 million | Q3 2022: $88.59 million | Q1 2023: $66.80 million | Q2 2023: $506.62 million | Q3 2023: $500.22 million | Q1 2024: $564.12 million | Q2 2024: $544.88 million | Q3 2024: $518.21 million | Q1 2025: $511.26 million | Q2 2025: $460.10 million | Q3 2025: $414.34 million.
- Over the full 6 years of available data (2020 to 2025), MoonLake Immunotherapeutics's Total Assets has grown by 263.9%.
- Historical annual values: Fiscal year 2025: $424.43 million | Fiscal year 2024: $477.93 million | Fiscal year 2023: $526.54 million | Fiscal year 2022: $76.84 million | Fiscal year 2021: $9.68 million | Fiscal year 2020: $116.63 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: